Sign up
TLX

Telix Pharmaceuticals Limited (NASDAQ: TLX)

Healthcare · Biotechnology

$8.96+0.11 (+1.19%)

Last close · Nov 18, 2026 · NASDAQ USD

Set alert

The Quantellect read. TLX rose 1.19% in the Nov 18 session to $8.96. The borrow fee is 15.05%. Three active firms cover the stock as of Nov 19, 2026; three active firms with targets average $21.33 over 12 months. Descriptive summary of the data on this page, not a recommendation.

Relative valuation—

—

MomentumNeutral

RSI (14) 47.0 (overbought above 70, oversold below 30)

Trend—

—

Short interest0.1% of float

FINRA settlement Oct 30, 2026

TLX price chart

Price $8.96 · As of Nov 18, 2026, 3:59 PM ET

Open full chart →
Price details unavailable for this range.

Chart loads when this section enters view.

Text price and event history
6M plotted price range (ET)
Range6M
First date—
Last date—
Open—
High—
Low—
Close—
Volume—
Plotted bars0

Plotted OHLCV bars

No price bars are available for this range.

Event records

Event records load after the price chart.

Split-adjusted daily prices · Price as of —

Initial 6M price range summary
Range6M
First close—
Last close—
High—
Low—
Volume—
Open
$9.00Nov 18, 2026 session
Previous close
$8.86Nov 17, 2026 close
Day range
$8.90 – $9.05Nov 18, 2026 session
52-week range—
Volume
416.13KNov 18, 2026 session
Average volume (30 calendar days)—
Market cap—
P/E (TTM)—
Forward P/E—
EPS (TTM)—
Dividend yielddata unavailable —
Beta (5-year monthly vs SPY)—

Price history

TLX · NASDAQ · USD

Split-adjusted · volume in shares

Price history unavailable

Notable price movement

— · Notable price movement not available

Options flow

— · Options flow not available

Q Score

— · Q Score not available

Quantellect signals

— · Quantellect signals not available

Industry comparison

— · Industry comparison not available

Upcoming events

— · Upcoming events not available

Analyst consensus

Buy

0Strong Buy
3Buy
0Neutral
0Sell
0Strong Sell

Based on 3 active firms as of Nov 19, 2026 (365-day activity window)

12-month price targets (third-party analysts)

Low$20.00
Average$21.33
High$22.00

As of Nov 19, 2026 across 3 active firms with targets. Targets are published by third-party analysts, not by Quantellect.

Full analyst forecast →

Earnings history

— · Earnings history not available

Smart-money activity

In the last 60 days: 0 insider sales and 0 purchases. No congressional trades in 90 days.

DateTypeWhoActionAmountSource
Insider buySmith Darren CharltonBuy$20.0KForm 4
Insider buyBehrenbruch ChristianBuy$497.2KForm 4
Insider buyBehrenbruch ChristianBuy$499.6KForm 4
All smart-money activity →

News and press releases

All TLX news →

Company profile

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops

CEO
Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., Ph.D
Headquarters
North Melbourne, VIC, Australia
Employees
1,120
IPO date
Nov 14, 2024
Sector
Healthcare
Industry
Biotechnology

Data sources: exchange quotes delayed 15 minutes, FINRA short interest, SEC filings, OPRA options data and third-party analyst data. Education only. Nothing on this page is a recommendation to buy or sell a security.